Agência Nacional of Vigilância Sanitária (Anvisa) approved the commercialization of Ozivy, the first synthetic semaglutide pen developed and manufactured at Brasil. The regulatory decision took place on Tuesday (26) and places the pharmaceutical company EMS in direct competition in the GLP-1 class medicine market. The product acts as an analogue of Ozempic, whose patent expired in March this year.
The authorization marks a change in the dynamics of the national pharmaceutical sector, which until then depended on imports to meet the demand for this type of treatment. Semaglutide is indicated primarily for the control of type 2 diabetes, acting to regulate blood glucose. The active ingredient also records high global demand due to its off-label use for the treatment of obesity and overweight.
Regulatory Classificação and differences for generic medicines
The Brazilian regulatory body classified the new drug as a new medicine, and not in the generic category. The country’s health legislation establishes specific guidelines for biological products and their derivatives, preventing the generic nomenclature for this class. The technical registration defines the substance as a synthetic analogue of a biological product.
The approval process required the presentation of complete clinical dossiers by the manufacturer. EMS filed the initial request in 2023, submitting data that proved the efficacy, safety and quality of the product in the national territory. Produtos with this classification undergo more rigorous scrutiny compared to traditional chemical pharmaceuticals.
Technical validation guarantees that the synthetic version presents the same expected therapeutic behavior in the patient’s body. The agency evaluated absorption, distribution, metabolism and excretion parameters of the molecule. The positive conclusion ends the scientific analysis phase and transfers the process to the economic regulation bodies.
Etapas mandatory before reaching pharmacy shelves
Health clearance does not authorize the immediate sale of the product in pharmaceutical retail. The medicine must undergo evaluation by Câmara of Regulação of Mercado of Medicamentos (CMED). Este interministerial body has the legal responsibility of defining the price ceiling for the commercialization of new treatments in the country.
Pricing analysis considers production costs, the value of competing therapies and the impact on the consumer market. Após publication of the maximum price on Diário Oficial from União, the manufacturer acquires the right to distribute the pens. The launch strategy, including the exact date on which the product will reach counters, remains the sole responsibility of the company.
Free access through the public health network requires a different and more complex administrative procedure. The incorporation into Sistema Único of Saúde (SUS) depends on a favorable opinion from Comissão Nacional of Incorporação of Tecnologias in SUS (Conitec). The committee evaluates the cost-effectiveness of the therapy compared to options already made available by the federal government.
Ministério of Saúde makes the final decision based on the committee’s technical report and budget availability. Atualmente, the public system provides other medications for diabetes control, but the inclusion of semaglutide pens would represent an update to clinical metabolic treatment protocols.
Fatores information about the new semaglutide pen
The introduction of the new treatment presents specific characteristics that reconfigure the supply of GLP-1-based therapies on the domestic market.
- The product is registered as a synthetic analogue and does not fall under generic legislation.
- Manufacturing takes place entirely at Brasil under the responsibility of the pharmaceutical industry EMS.
- The Anvisa endorsement attests to the safety standards and glycemic control capacity of the formula.
- Private trading depends on the setting of values by Câmara of Regulação of Mercado of Medicamentos.
- Distribution by SUS requires prior analysis of financial impact and clinical effectiveness by Conitec.
- The formulation enters into direct competition with Ozempic and other consolidated brands in the segment.
The structuring of a local production chain reduces the vulnerability of the Brazilian market to exchange rate fluctuations and international supply problems. The national production of highly complex inputs strengthens the autonomy of the country’s pharmaceutical industrial park.
Impacto economic and patent breaking in the pharmaceutical sector
The competitive scenario underwent a structural change with the patent loss of the reference medicine in March. The loss of commercial exclusivity opened the market for the development of therapeutic alternatives by other laboratories. Ozivy stands out as the first practical result of this regulatory opening approved by Brazilian authorities.
The entry of a national competitor has the potential to generate an adjustment in retail prices. Historicamente, the breakup of monopolies in the medicine sector results in more accessible options for consumers who depend on prescriptions in the private network. The fight for market share tends to benefit patients undergoing continuous treatment.
The GLP-1 receptor agonist segment, which includes brands such as Saxenda and Ozempic, records record revenue volumes on a global scale. The effectiveness of these molecules in delaying gastric emptying and signaling satiety to the brain boosted demand exponentially. The national industry is now seeking to capture a portion of this economic growth.
Perspectivas for metabolic treatment in Brasil
The development of synthetic analogues requires significant investments in research, technology and manufacturing infrastructure. The approval of the EMS dossier demonstrates the technical capacity of Brazilian laboratories to operate in the advanced therapies segment. The regulatory framework establishes a precedent for the evaluation of future applications for registration of similar formulations.
Especialistas in endocrinology monitor the expansion of the therapeutic arsenal available in the country. The diversification of brands makes it easier to adhere to long-term treatments, an essential factor in controlling chronic diseases. The availability of multiple semaglutide options in pharmacies creates an environment of supply stability, mitigating the risks of shortages that have affected patients in recent years.